Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: Summary of clinical trials

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 251-260

  Logan, J Wells ^a   Moya, Fernando R ^a  

^a NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Phospholipids; Respiratory distress syndrome; Surfactant; Surfactant proteins

Indexed keywords

BERACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; LUNG SURFACTANT; PHOSPHOLIPID; PORACTANT; PUMACTANT; SURFACTANT PROTEIN B;

CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MORTALITY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; OXYGEN SUPPLY; PNEUMOTHORAX; REVIEW; TREATMENT OUTCOME; VENTILATOR; WEANING;

EID: 75749094790     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Jobe AH. Antenatal associations with lung maturation and infection. J Perinatol. 2005;25 Suppl 2(2):S31-35.
2. Hoekstra RE, Jackson JC, Myers TF, Frantz ID 3rd, Stern ME, Powers WF, et al. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics. 1991;88(1):10-18.
3. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: An observational study of neonates weighing 601 to 1300 grams at birth. The members of the national institute of child health and human development neonatal research network. Pediatrics. 1993;92(2):191-196.
4. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med. 1994;330(21):1476-80.
5. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001;2(2):CD000144.
6. Suresh GK, Soll RF. Lung surfactants for neonatal respiratory distress syndrome: Animal-derived or synthetic agents? Paediatr Drugs. 2002;4(8):485-492.
7. Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: Defi ciency of pulmonary surfactant protein b in congenital alveolar proteinosis. N Engl J Med. 1993;328(6):406-410.
8. Nogee LM, Dunbar AE, 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein c gene associated with familial interstitial lung disease. N Engl J Med. 2001;344(8):573-579.
9. Sinha S, Moya F, Donn SM. Surfactant for respiratory distress syndrome: Are there important clinical differences among preparations? Curr Opin Pediatr. 2007;19(2):150-4.
10. Mazela J, Merritt TA, Gadzinowski J, Sinha S. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases. Acta Paediatr. 2006;95(9):1036-1048.
11. Moya F, Maturana A. Animal-derived surfactants versus past and current synthetic surfactants: Current status. Clin Perinatol. 2007;34(1):145-177, viii.
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
13. Pfi ster RH, Soll RF. New synthetic surfactants: The next generation? Biol Neonate. 2005;87(4):338-344.
14. Kattwinkel J. Surfactant. Evolving issues. Clin Perinatol. 1998;25(1): 17-32.
15. Moya FR, Hoffman DR, Zhao B, Johnston JM. Platelet-activating factor in surfactant preparations. Lancet. 1993;341(8849):858-860.
16. Hamvas A, Nogee LM, Mallory GB Jr, Spray TL, Huddleston CB, August A, et al. Lung transplantation for treatment of infants with surfactant protein b defi ciency. J Pediatr. 1997;130(2):231-239.
17. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, et al. Comparison of infasurf (calf lung surfactant extract) to survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics. 1997;100(1):31-38.
18. Attar MA, Becker MA, Dechert RE, Donn SM. Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: A controlled trial. J Perinatol. 2004;24(10):626-630.
19. Bloom BT, Clark RH. Comparison of infasurf (calfactant) and survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics. 2005;116(2):392-399.
20. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr. 2003;162(7-8):476-480.
21. Hammoud M, Al-Kazmi N, Alshemmiri M, Thalib L, Ranjani VT, Devarajan LV, et al. Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome. J Matern Fetal Neonatal Med. 2004;15(3):167-175.
22. Yalaz M, Arslanoglu S, Akisu M, Atik T, Ergun O, Kultursay N. A comparison of effi cacy between two natural exogenous surfactant preparations in premature infants with respiratory distress syndrome. Klin Padiatr. 2004;216(4):230-235.
23. Speer CP, Gefeller O, Groneck P, Laufkotter E, Roll C, Hanssler L, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1995;72(1):F8-13.
24. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. A randomized, multicenter masked comparison trial of poractant alfa (curosurf) versus beractant (survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol. 2004;21(3):109-119.
25. Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr. 2005;94(6):779-784.
26. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National institute of child health and human development neonatal research network. J Pediatr. 1993;123(5):757-766.
27. Sehgal SS, Ewing CK, Richards T, Taeusch HW. Modifi ed bovine surfactant (survanta) versus a protein-free surfactant (exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study. J Natl Med Assoc. 1994;86(1):46-52.
28. VTOxford. A multicenter, randomized trial comparing synthetic surfactant with modifi ed bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-oxford neonatal network. Pediatrics. 1996;97(1):1-6.
29. Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV. Comparative effi cacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol. 1997;17(6):455-460.
30. da Costa DE, Pai MG, Al Khusaiby SM. Comparative trial of artifi cial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: Experiences in a developing country. Pediatr Pulmonol. 1999;27(5):312-317.
31. Kukkonen AK, Virtanen M, Jarvenpaa AL, Pokela ML, Ikonen S, Fellman V. Randomized trial comparing natural and synthetic surfactant: Increased infection rate after natural surfactant? Acta Paediatr. 2000;89(5):556-561.
32. Ainsworth SB, Beresford MW, Milligan DW, Shaw NJ, Matthews JN, Fenton AC, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: A randomised trial. Lancet. 2000;355(9213):1387-1392.
33. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ, et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr. 1996;128(3):396-406.
34. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005;115(4):1018-1029.
35. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005;115(4): 1030-1038.
36. Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings NJ, Jung AL, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics. 1997;100(1):39-50.
37. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001;2(2):CD000510.
38. Bernhard W, Mottaghian J, Gebert A, Rau GA, von Der HH, Poets CF. Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1524-1533.
39. Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2007;17(4):CD006069.